Felodipine Tablet, Film Coated
Product Images NDC 51407-089

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 51407-089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (1 Formula)

Image Description (1 Formula)
Chemical structure diagram of Felodipine, showing its molecular arrangement with labeled atoms including carbon, hydrogen, chlorine, oxygen, and nitrogen.*
FDA Label Image

51407-087-01lb.jpg (51407 087 01lb)

51407-087-01lb.jpg (51407 087 01lb)
Label for Felodipine extended-release tablets USP, 2.5 mg strength, containing 100 tablets, labeled by Golden State Medical Supply, Inc. The label includes NDC 51407-087-01, storage instructions, and a note to see the package insert for dosage information. It is marked Rx only.*
FDA Label Image

51407-088-01lb.jpg (51407 088 01lb)

51407-088-01lb.jpg (51407 088 01lb)
Label for Felodipine extended-release tablets USP, 5 mg strength, containing 100 tablets. The label includes the NDC number 51407-088-01 and states the product is for Rx only. It also provides storage instructions and directions for use. The labeler is Golden State Medical Supply, Inc.*
FDA Label Image

51407-089-01lb.jpg (51407 089 01lb)

51407-089-01lb.jpg (51407 089 01lb)
Label for Felodipine extended-release tablets, USP, 10 mg strength, containing 100 tablets. The label indicates prescription use only and includes storage instructions. The labeler is Golden State Medical Supply, Inc.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
A clinical data table presenting mean reductions in blood pressure (mmHg) for Felodipine across two studies over 8 and 4 weeks. It details dose groups, number of participants, systolic/diastolic mean peak response, mean trough response, and trough/peak ratios, with footnotes on placebo subtraction and sample size differences.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
Data table showing the percent of patients experiencing adverse events in controlled trials of Felodipine extended-release tablets as monotherapy, by body system and dosage (placebo, 2.5 mg, 5 mg, 10 mg). Incidence rates and discontinuations are listed for categories including cardiovascular, digestive, nervous, respiratory, and skin events across these dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.